Prof. S. Shakir Jamil Director General

CCRUM, Department of AYUSHNew Delhi

10th Knowledge Millenium Summit-2013

“Curing the Incurables: Sharing of Innovation”16th January, 2013, Vigyan Bhavan, New Delhi

Role of Unani Medicine as Adjuvant therapy in Chronic & Incurable

Diseases

Unani System of Medicine originated from Greece

The philosophical doctrines of the System was laid down by Hippocrates. (460-377 BC)

Arab, Central Asian and European countries contributed to the system.

From Central Asia Unani Medicine traversed to India

2

• Today, India is the world leader in Unani Medicine having largest set up of educational, healthcare and research facilities.

• Unani medicine is also recognized, practiced and popular in Pakistan, Bangladesh, Malaysia, Sri Lanka and South Africa.

• Also Practiced in Kuwait, Dubai & Saudi Arabia etc.

Tabiyat (Medicatrix naturae)

Mizaj (Temperament)

Akhlat (Body Humours)

Usool-e- Ijaj (Principles of treatment) including Ilaj-bit-Tadbir (Regimenal Therapy)

Research & Development

5

CCRUM Central Council for Research in Unani Medicine

(CCRUM) was established by Government of India as apex organization for Research and Development activities in Unani System of Medicine in 1979.

The Council is an autonomous organization under Department of AYUSH, Ministry of Health & Family Welfare, Govt of India.

7

CCRUM - Mandate

8

Research in Unani Medicine on scientific lines.

To initiate, aid, develop and coordinate scientific research of Unani Medicine.

To finance researches meant for furtherance of objective of the CCRUM.

To exchange information with other institutions.

To prepare and publish literature on Unani medicine.

Research Programmes

Pre-clinical/Safety Studies

Clinical Research

Fundamental aspects of Unani Medicine

Drug Standardization including SOPs for Unani drugs

Literature including Medico-historical Research

Ethno-botanical Survey, Collection and Cultivation of Unani Medicinal Plants

IEC and other Research oriented programmes

Pharmacological action/safety evaluation 22 drugs

Number of diseases clinically studied 22

Clinical trials completed 13 drugs

Number of drugs under trial 30

Validation of safety & efficacy of Unani pharmacopoeial

Drugs.

•Number of formulations 25

•Number of diseases under study 10

12

• Bars (Vitiligo)

• Naar-e- Farsi (Eczema)

• Taqashshur-e-Jild (Psoriasis )

• Zeequn-Nafas (Bronchial asthma )

• Zaght-ud- Dam Qawi (Hypertension)

• Daa-ul-Feel (Filariasis)

• Iltehaab-e-Mafasil (Rheumatoid

arthritis)

• Iltehaab-e-Tajaweef-e-Aanaf (Sinusitis)

Validation of Unani Fundamentals

Study on susceptibility of acquiring diseases in relation to Mizaj (temperament).

Study on molecular interpretation of individual temperament at CRIUM, Hyderabad

in collaboration with Center for Cellular and Molecular Biology, CSIR, Hyderabad.

Literary Research

Translation of classical books/manuscripts in different languages.

51

Books/brochures/leaflets and IEC material in different languages.

25

Reprint of rare classical books 88

Standardization of Unani Terminology 4000 terms

All India Institute of Medical Sciences, (AIIMS) New Delhi. Vallabh Bhai Patel Chest Institute, University of Delhi, New

Delhi. Jamia Hamdard (Hamdard University), New Delhi. KGMC, Lucknow. Ibn-e-Sina Academy, Aligarh. Centre of Liver diseases Deccan Med. College, Hyderabad Taramani Hospital & Res. Centre, Chennai. Osmania General Hospital Hyderabad.

With the financial support by DST for creating research infra-structure two facilities were created:

Clinical Research facilitiy at CRI, Hyderabad. Pre-clinical research facilitiy at RRI, Srinagar.

• Centre for Research in Indian Systems of Medicine (CRISM) in University of Mississippi, USA

• UNANI CHAIR at University of Western Cape, South Africa

• UNANI CHAIR at Sri Lanka is in process

Thrust areas:Thrust areas:

Immuno-modulationImmuno-modulation To prevent drug toxicityTo prevent drug toxicity To improve Quality of LifeTo improve Quality of Life

Unani Medicine as Adjuvant therapy

Areas Cognitive impairment

Tuberculosis (especially MDR TB)

Cancer

HIV / AIDS

Unani Medicine as Adjuvant therapyContd

..

Study 1

Cognitive impairment Title:

Evaluation of a Unani Formulation for Improving Cognitive Impairment in Children with Cerebral Palsy and Mental Retardation

The study was conducted at Majeedia Hospital, Jamia Hamdard in collaboration with UDAAN an NGO working for disabled children.

This was a controlled study in which both groups were given physiotherapy and special education but one group was given Unani formulation and other group HBOT.

The study was conducted on current clinical parameters following the GCP.

Objective:To prove efficacy of Unani formulation in the treatment of Neurodevelopmental disabilities with special emphases on cognitive improvement in Cerebral Palsy (C.P.) and/or Mental Retardation (M.R.).

Outcome: Long term amelioration of associated behavioural and

neurological problems Improvement in memory and cognitive functions Improvement in musculo-skeletal deformities

Unani Medicine as Adjuvant therapyContd..

Study 2

Title: Study on management of Pulmonary Tuberculosis with herbal Unani product (0394) as an adjuvant drug .

The study was sponsored by Panacea Biotech and conducted at Majeedia Hospital, Jamia Hamdard, Hamdard Nagar, New Delhi.

This was a controlled study in which ATT was given to both groups and only one group was given Unani adjuvant formulation along with ATT.

The study was conducted on current clinical parameters following the GCP.

Objective:

To evaluate the efficacy of Unani formulation in enhancement of resolution rate in Pulmonary Tuberculosis including MDR.

Outcome: Fast resolution of infiltration in chest. Faster sputum clearance for AFB. Better response in MDR cases.

Unani Medicine as Adjuvant therapy

Study 3

Title: Clinical evaluation of a Unani formulation for prevention ofhepato-nephro toxicity in Pulmonary Tuberculosis.

(The study was conducted at Majeedia Hospital, Jamia Hamdard.This was a controlled study in which both groups were given ATT and

one group was Unani Hepato-protective formulation.The study was conducted on current clinical parameters following the

GCP.

Objective:To evaluate efficacy of Unani formulation in the treatment of Pulmonary Tuberculosis with reference to prevention of hepato-nephro toxicity.

Unani Medicine as Adjuvant therapy

Unani Medicine as Adjuvant therapy

Unani Medicine as Adjuvant therapy

HIV / AIDS• Objective of the study is to improve, enhance and

potentiate body immunity and to improve the Quality of Life in HIV/AIDS patients.

• Feasibility study has been conducted. Detailed planning and protocol designing at RRIUM, Mumbai in collaboration with J.J. Hospital, Mumbai.